Hart Blik . nl - Gezien vanuit het hart!
John Jacobs
  • John
    • Over mij
    • About me
  • COVID-19 overzicht
    • Covid is niet voorbij
    • Oversterfte in Europa
    • Groepsimmuniteit weer opnieuw bekeken >
      • ​1. Over groepsimmuniteit. Giwob
      • 2. Drie mislukte pogingen. GIwob
      • ​3. Bereken de kosten. GIwob
      • 4. Onvolledige immuniteit. Giwob
      • 5. Wat zou er mis kunnen gaan? GIwob
      • 6. Wat kunnen we doen? GIwob
      • 7. Kort & krachtig! GIwob
    • Simpel&complex
    • Viruscontrole
    • Meer negativiteit
    • Epidemie controle
    • 2jaar-COVID19
    • Humanitair
    • Vragen >
      • Vragen over ziekte
      • Vragen over vaccins
      • Vragen over immuniteit
      • Vragen over Epidemie
      • Vragen over mutaties
      • Vragen over politiek
    • Gezondheidsraad
    • VirusEthiek >
      • Effectief en open strijden
      • Gaan we voor het goede?
      • Ziektecijfers
      • Vaccinatie
      • Preventie besmettingen
    • Virusmutaties
    • Bijzondere immuniteit
    • infectie zonder ziekte
    • Onnavolgbaar beleid dat verkeerd uitpakt >
      • Hoe goed bestrijden we COVID-19 ?
      • Gevaarlijk
      • Stoppen
      • Zijn de vaccins goed?
      • Beschermen vaccins tegen infectie?
      • Maakte Nederland de juiste keuzes?
      • Achterkamertjes geheimen
      • Wat zou Nederland moeten gaan doen?
      • Kanttekeningen
    • Afweer en vaccin >
      • IFR
      • Immuunreacties
      • Verschillende vaccins
      • Studies en resultaten
      • Een vaccin en dan?
    • Vaccinatieplan
    • Epidemiebestrijding herzien >
      • Epidemiebestrijding herzien. Strategie
    • Test, traceer & isoleer
    • Palet aan testen
    • Besmetting voorkomen
    • Geen groepsimmuniteit
    • Geen vaccin
    • Ziekte COVID-19
    • Advies VWS
    • 1953 versus 2020
    • Onder de loep >
      • RIVM virus bestrijding
    • Dwalen op bekend terrein
    • Dashboard >
      • Dashboard. I
    • Humanitair
    • Foute afweer
    • Betere bestrijding van de epidemie >
      • Beter (A) Impact COVID-19
      • Beter (B) Tussen complot en kritiekloos
      • Beter (C) Verschillende strategieën
      • Beter (D) Vaccin of beter maken
    • Cijfers en data >
      • Mutations
    • Bestrijding COVID19
    • Mondkapjes
    • Model leren voor beter handelen >
      • Model leren voor beter handelen 3
      • Model leren voor beter handelen 4
      • Model leren voor beter handelen 5
      • Model leren voor beter handelen 6
      • Model leren voor beter handelen 7
    • Verloren door te weinig kennis
    • Ontelbaar op waarde geschat
    • Rekenen zonder getallen
    • Versimpeld model Corona NL >
      • Addendum. Correctie
      • Erratum
    • FAQ - COVID-19 >
      • FAQ. Epidemie
      • FAQ. Model
      • FAQ. Bestrijding
      • FAQ. Ziekte
      • FAQ. Coronavirussen
    • Reacties
    • Immuniteit en antistoffen >
      • Rekenen zonder getallen 7
      • Model leren voor beter handelen 2
    • Platform BZC
  • Medisch & biologie
    • Schepping & evolutie
    • Schepping verbeteren
    • Niet-sterieliserende slijmvlies immuniteit
    • Willem den Otter. In Memoriam
    • Luchtvervuiling doodt >
      • Luchtvervuiling doodt1
      • Luchtvervuiling doodt. 2
      • Luchtvervuiling doodt. 3.
      • Luchtvervuiling doodt. 4.
      • Luchtvervuiling doodt. 5.
    • Voorkom epidemie
    • Expert opinion
    • Ongezonde gezondheid
    • HPV
    • Ontsnappende virussen
    • Eiwit evolutie >
      • Afweer ontwerp
    • Tumor immunologie
    • Huidveiligheid
  • Samenleving
    • Schepping & evolutie
    • Schepping verbeteren
    • ORTEC blogs >
      • P4O2-COVID19
      • U-Prevent
      • Clinical decision support
      • Data voor betere patiëntenzorg
    • Licht & helderheid verschaffen.
    • AI summerschool (NL)
    • Racisme
    • Kwaadaardig complotten
    • Drie complotten
    • Bang
    • Onvrede en vrede
    • Schoppentroef
  • Federa
    • Federa deelnemers
  • English blogs
    • Covid is not over
    • ExcessMortalityEEA
    • Effective and open
    • Range of tests
    • SupplementEM
    • Virus Ethics >
      • Do we strife for the good things?
      • Disease outnumbered
      • Special immunity
      • Vaccination
      • Immune responses and vaccin >
        • Immune responses
        • Different vaccines
        • Trials and results
        • Next steps
        • Prevention of epidemic
        • Vaccinationwise
    • Non-sterile mucosal immunity
    • Contamination
    • No herd immunity >
      • Questions on COVID-19 >
        • Disease
        • Vaccine >
          • Immunity
        • Epidemics
        • Poltics
        • IFR
    • Test, trace & isolate
    • No vaccine
    • Disease
    • Lost at familiar property
    • Corona Dashboard
    • Fighting COVID19
  • ORTEC in English
    • P4O2-COVID19
    • Data science for better treatment of leukemia.
    • U-Prevent [EN]
    • Clinical decision support [EN]
    • Data to improve patient care
  • Linkpagina

COVID-19

Foto

Immune responses and vaccines

Foto

Various Immune responses 

John Jacobs, 28.11.2020. 

Foto

Twee componenten

Our immune system consists of two components that cooperate efficiently: the innate and antigen- specific immune system (Figure 2). Both components use thousands of variants of hundreds of molecules. These molecules can be markers on cells (CD antigens), proteins in cells, communication proteins between cells (cytokines) or proteins that perform defense functions, like cell-killing proteins, complement and coagulation proteins. Due to the endless variations on a theme, the immune system can fine-tune responses with great finesse. Most of the immune system is redundant, making it mostly resistant against major consequences of small genetic errors, like functional single gene knock outs. People lacking functional interferon beta are extremely susceptible to serious viral infections such as COVID-19. The strength of natural defenses mainly depends on a person's diet, condition, age, and lifestyle. Vitamine D and interferon-beta are important factors for a healthy natural immune system.
​
Innate immunity recognizes and fights danger in the body. Danger could be a known pathogenic structure such as a virus, but also a physical process like cell death. In case of danger, the antigens are taken from the tissue and presented to the specific immune system.
Foto
Figure 2. Innate and antigen-specific immunity.
(1) The innate immune system recognizes danger, i.e. cell death or a generic pathogen structure, like dsRNA. (2) Dendritic cells present the antigen to the antigen-specific immune system (i.e. B, Tc and Th cells, see Figure 4). (3) The antigen-specific immune system amplifies by clonal expansion to a highly specific and highly effective immune response. (4) The antigen-specific immune system orchestrates anti-pathogen immune responses both by antigen-specific and innate mechanisms.


Virus-specific immunity

Antigen-specific immunity excels in recognizing small pathogen structures (often proteins) and developing and sustaining immunological memory for more efficient elimination upon re-exposure. When the antigen-specific immune system is strong enough to prevent symptomatic disease, we call it immunity. If the immune response also prevents infection, it is dubbed sterilizing immunity. Infection means replication of the pathogen, i.e. virus in humans. Biology has evolutionary design principles to create endless variations for antigen recognition. Virus-specific defenses can be antibodies could be derived from B cells or cellular defenses from cytotoxic T cells (Tc). Virus infection leads to production of virus proteins in a cell and free virus outside the cell (Figure 3). Protein production in a cell is necessary to get cytotoxic (cell-killing) T (Tc) cells. These Tc kill infected cells (cellular immunity) but are not effective against free virus.

Virus infection triggers to production of viral proteins in the cell and free virus outside the cell (Figure 3). Protein production in a cell is a prerequisite to develop cytotoxic  T (Tc) cells. These Tc kill infected cells (cellular immunity) but are not effective against free virus. Virus-binding antibodies are produced by B cells against free virus.

Antibodies do not enter the cell but can neutralize free virus. Virus with antibodies is more difficult to breed and is less likely to infect other people. It has not been shown that antibodies protect against disease, as people who are seriously ill have the highest titers of neutralizing antibodies.
Foto
Figure 3. Virus infection and immunology.
Features: [B] B cell; [C] cell cytoplasm; [I] cytoplasm of infected cell. [N] Nucleus Core with DNA; [R] ACE-2 Receptor; [rS] Virus RNA encoding Spike protein; [rV] Virus RNA encoding cellular genes; [S] Virus Spike Protein that Binds to the ACE-2 Receptor for Infection. [Tc] cytotoxic T cell; [V] virus.
Steps: [1] The SARS-2 virus binds to the ACE-2 Receptor on the cell. [2] Receptor binding induces membrane fusion, and the virus enters the cell's cytoplasm. [3] The virus dismantles, and the viral RNA and enters the cell. This RNA codes for virus replication genes, virus proteins and dysregulation and activation of the immune system. [4] The viral RNA is replicated in the cell by the virus RNA polymerase. [5] Virus proteins are produced by translating the viral mRNA in the cell. [6] Viral peptides are presented in the context of MHC I to cytotoxic T cells [Tc]. [7] Free virus is produced. B cells make antibodies recognizing free virus.
Not shown: Steps 6 + 7 are supported by the fact that special immune cells (dendritic cells; DC) present small pieces of virus proteins in the context of MHC-II to helper T cells [Th].


Immune specialization

Different immune responses are orchestrated by different helper T cell (Th) phenotypes. These Th strengthen immunological choices it (Figure 1). In general, this is an advantage in fighting diseases, since most often this is the most efficient way to eliminate pathogens. Occasionally it is a disadvantage, like when people have allergic overreactions that increases with subsequent exposure, resulting in the infamous anaphylactic shock. In this condition, the immune system may suddenly switch from active protection to tolerance trying to prevent self-destruction.
​
Most immunologists think that antibodies are more important in defense against bacteria and cellular defense is more important against viruses. Cellular immunity is capable of killing cells that produce viruses. It should be noted that this is complex immunology with many views and exceptions, not least because of the infinite virus escape strategies.
The immunologic complexity is crucial in understanding the virus immune disease called COVID-19. Early choices in immune response, e.g. triggered by a vaccine or a previous infection, could have a major influence on the immune system later in the infection or in a subsequent infection.
Foto
Figure 4. Orchestration of immune responses by T-Helper cells.
See also Figure 3. Additional parts: [B] B-cell; [DC] Dendritic cell; [Tc] cytotoxic T cell; [Th1] T helper type 1; [Th2] T helper type 2; [Tr] Regulator T cell (Th-like cell that promotes tolerance). [Ts] Suppressor T cell, Tc-like cell that actively protects the tissue against immune reactions.
Steps: Dendritic cells present antigen in MHC-II [1] When presented to T helper type 1 cells, these will stimulate cytotoxic T cells. Cytotoxic T cells kill virus infected cells. [2] When presented to T helper type 2 cells, these B cells will stimulate antibody production. Antibodies are efficient in cleaning up free virus. [3] When presented to regulator T cells, they will stimulate antigen-specific tolerance. These cells actively protect tissue. This is important to prevent the immune system from rejecting its own healthy tissue. This scheme is a simplification, since there are an infinite number of variations within each immunological route. 


Different immunity

Coronaviruses have a special relationship with the immune system. Similar to the corona cold viruses, SARS-2 triggers an immune response that causes disease, only COVID-19 is much more serious than the common cold. Immune responses against respiratory viruses (influenza (flu), coronaviruses, RSV and rhinoviruses) generally yield immunity against the disease without immunity to the virus. People who are immune can still infect others, which undermines herd immunity.

Several internal coronavirus proteins have high sequence homology. Immune reactions against those proteins could cause cross-immunity by antibodies or cellular immunity. This could explain why children, in whom the cold literally is common, are less likely to become ill from SARS-2. Interestingly, children rarely produce antibodies against COVID-19. The Spike protein used in the vaccines differs too much between coronaviruses to anticipate any form of cross-immunity against this protein.

The Spike protein triggers the strongest immune response. Immunity against corona cold viruses lasts only shortly, and within one year people become reinfected and ill again. Neutralizing antibodies may spread the virus throughout the body. In SARS-1, worsening of lung disease was seen after virus exposure.
Foto
Figure 5. Antibody-dependent enhancement of infection (ADE)
The effects at the cellular level (left) and at the organ level (right) are shown in all images. The tissue is the lungs in (A) and (C), and the blood circulation in (B) and (D). (A) In individuals without neutralizing antibodies, SARS-2 virus efficiently infects lung cells. (B) White blood cells (macrophages / monocytes [M]) cannot be infected since they do not have the receptor for virus entry. (C) When a person has antibodies, everything changes. This could be in a later phase of the disease (e.g. during disease worsening), or of repeated infection and after vaccination. Antibodies protect against infection of lung cells, and thus reduce lung disease. (D) Antibodies bind to SARS-2 and to macrophages. The antibody acts as a virus receptor for the macrophage that is infected (ADE). Infected macrophages circulate throughout the body to spread the SARS-2 virus. The virus and virus infection are indicated in red.


Foto

Immune responses and vaccines
Immune responses
Different vaccines
Trials and results
Vaccination and next steps
Foto

John Jacobs
28.11.2020

Powered by Maak je eigen unieke website met aanpasbare sjablonen.